204 related articles for article (PubMed ID: 3881300)
21. Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
Stanway SJ; Delavault P; Purohit A; Woo LW; Thurieau C; Potter BV; Reed MJ
Oncologist; 2007 Apr; 12(4):370-4. PubMed ID: 17470679
[TBL] [Abstract][Full Text] [Related]
22. Aromatase in the context of breast and endometrial cancer. A review.
Jongen VH; Hollema H; Van Der Zee AG; Heineman MJ
Minerva Endocrinol; 2006 Mar; 31(1):47-60. PubMed ID: 16498363
[TBL] [Abstract][Full Text] [Related]
23. Low-dose aminoglutethimide in treatment of advanced breast cancer.
Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
[TBL] [Abstract][Full Text] [Related]
24. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
25. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
26. [Aminoglutethimide therapy in advanced breast cancer].
Kühböck J; Ludwig H; Pötzi P; Zielinski C
Wien Med Wochenschr; 1985 Dec; 135(23-24):608-11. PubMed ID: 4096007
[TBL] [Abstract][Full Text] [Related]
27. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
28. Aromatase inhibitors in breast cancer therapy.
Brueggemeier RW
Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
[TBL] [Abstract][Full Text] [Related]
29. Closing remarks to the conference, Aromatase: New Perspectives for Breast Cancer.
Lipton A; Harvey HA; Santen RJ
Cancer Res; 1982 Aug; 42(8 Suppl):3468s. PubMed ID: 7083210
[No Abstract] [Full Text] [Related]
30. [The effect of aminoglutethimide on steroid synthesis of the adrenal gland and its use in prostate cancer].
Knönagel H; Hauri D
Helv Chir Acta; 1989 Aug; 56(3):347-50. PubMed ID: 2807964
[TBL] [Abstract][Full Text] [Related]
31. Aromatase, its inhibitors and their use in breast cancer treatment.
Brodie AM
Pharmacol Ther; 1993 Dec; 60(3):501-15. PubMed ID: 8073072
[TBL] [Abstract][Full Text] [Related]
32. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
MacNeill FA; Jones AL; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1992 Oct; 66(4):692-7. PubMed ID: 1419608
[TBL] [Abstract][Full Text] [Related]
33. [Aminoglutethimide in the treatment of metastasizing breast carcinoma in old age].
Gorgone S; Lorenzini C; Palmeri R; Belnome N; Calbo L; Dattola P; Melita P
Chir Ital; 1987 Apr; 39(2):166-75. PubMed ID: 3652316
[TBL] [Abstract][Full Text] [Related]
34. Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1980 Sep; 51(3):473-7. PubMed ID: 6773974
[TBL] [Abstract][Full Text] [Related]
35. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
Lønning PE; Kvinnsland S; Thorsen T; Ueland PM
Clin Pharmacokinet; 1987 Dec; 13(6):393-406. PubMed ID: 3436111
[TBL] [Abstract][Full Text] [Related]
36. Aminoglutethimide and ketoconazole: historical perspectives and future prospects.
Shaw MA; Nicholls PJ; Smith HJ
J Steroid Biochem; 1988 Jul; 31(1):137-46. PubMed ID: 2969435
[TBL] [Abstract][Full Text] [Related]
37. Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.
Lønning PE
Cancer Chemother Pharmacol; 1990; 26(4):241-4. PubMed ID: 2369789
[TBL] [Abstract][Full Text] [Related]
38. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Dowsett M; Santner SJ; Santen RJ; Jeffcoate SL; Smith IE
Br J Cancer; 1985 Jul; 52(1):31-5. PubMed ID: 4015950
[TBL] [Abstract][Full Text] [Related]
39. Clinical use of aromatase inhibitors in the treatment of breast cancers.
Manni A
J Cell Biochem Suppl; 1993; 17G():242-6. PubMed ID: 8007705
[TBL] [Abstract][Full Text] [Related]
40. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
